BioSpace News Archive

Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics today announced the presentation of eight posters during the Fall Clinical Dermatology Conference, which takes place Oct. 21-24, 2021.

D&D Pharmatech Inc. today announced that it as completed a $51 million Series C round of financing led by Praxis Capital Partners, other investors included DS Asset Management, Kudos Ventures and Korea Investment & Securities.

Cybin Inc. today announced the completion of its 74th pre-clinical study as it continues to progress its proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies.

AVROBIO, Inc. today reported new safety data from the first lentiviral gene therapy clinical trials for Fabry disease and Gaucher disease, as well as new high-resolution cellular data providing insights into the mechanisms of action of its gene therapies.

ANANDA Scientific Inc ., a biotech pharma company, announced a clinical trial to evaluate Nantheia™ ATL5 , an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology for Opioid Use Disorder. An Investigational New Drug (IND) application has been approved by the U.S. Food and Drug Administration (FDA) for this trial.

Humanigen, Inc. today announced a late-breaking (LB) presentation of results from the Company’s randomized, double-blind, placebo-controlled LIVE-AIR Phase 3 study at the CHEST Annual Meeting 2021, which is being hosted by the American College of Chest Physicians® (CHEST) virtually from October 17th to October 20th.

Castle Biosciences, Inc. today announced it has signed a definitive agreement to acquire Cernostics, Inc. (Cernostics), an Illumina Ventures company.

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the U.S. Food and Drug Administration (FDA) for a planned Phase 2 study of the company’s drug Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer.

Artizan Biosciences, Inc., a biotechnology company at the frontier of microbiome precision medicine, announced the appointment of Bridget Martell, M.A., M.D., as President and Chief Executive Officer.

Locus Biosciences, Inc. today announced that the company has entered a credit facility of up to $25 million with Hercules Capital, Inc. (NYSE: HTGC), a specialty financing lender for life science and technology companies.